瑞银：中国生物科技企业上半年销售大多胜预期下半年全球研发催化剂成关键首选百济神州(ONC.US)

7 9 月, 2026

One Min Read

1 Views

Last Update: 7 9 月, 2026

Written By

Other Articles

Previous

Treasury yields face 4.8% test as fiscal risks threaten to spill into other assets

Next

麦科田(02041)正式登陆港交所三大业务协同打造港股医疗设备板块又一标杆

Related Posts

先消灭低价股！

1 Min Read

假期市场思考：A股还是美股？

1 Min Read

香港证券两日成交额破百亿！港股仍有市场？

1 Min Read

Our site uses cookies. By using this site, you agree to the Privacy Policy and Terms of Use.

Accept